<style>
    body {
        line-height: 1.6;
    }

    .header {
        width: 100%;
        max-width: 1024px;
        margin: 0 auto;
        overflow: hidden;
    }

    .header img {
        width: 100%;
        height: auto;
        display: block;
        border-radius: 20px;
    }

    .main-content {
        display: flex;
        gap: 20px;
        margin: 10px 0;
    }

    .intro-objectives {
        display: flex;
        gap: 20px;
        width: 100%;
    }

    .intro-objectives .section {
        flex: 1;
        max-width: none;
    }

    .intro-objectives .section:first-child {
        flex: 2;
    }

    .intro-objectives .section:last-child {
        flex: 1;
    }

    .section-block {
        display: flex;
        gap: 20px;
        margin: 10px 0px 0px 0px;
    }

    .section {
        padding: 25px;
        background-color: #e5e5e5;
        border-radius: 20px;
        margin: 10px 0px 10px 0px;
    }

    .section-title {
        font-size: 1.5em;
        font-weight: bold;
        margin-bottom: 10px;
        color: #2F4890;
    }

    .section-subtitle {
        font-size: 1.2em;
        font-weight: bold;
        text-align: center;
        margin-top: 15px;
        margin-bottom: 10px;
        color: #2F4890;
    }

    .interactive-element {
        padding: 0px;
        margin: 0px 0;
    }

    .button-container {
        display: flex;
        justify-content: center;
        gap: 10px;
        margin-bottom: 15px;
    }

    .expand-btn {
        background-color: #7C9F87;
        color: white;
        border: none;
        padding: 10px 15px;
        cursor: pointer;
        border-radius: 5px;
    }

    .expand-btn.active {
        background-color: #86759D;
    }

    .hidden {
        display: none;
    }

    .intro-list li,
    .objectives-list,
    .conclusions-list {
        display: flex;
        flex-direction: column;
        justify-content: space-between;
        list-style-type: none;
        padding-left: 0;
    }

    .intro-list li,
    .objectives-list li,
    .conclusions-list li {
        background-color: #F2F2F2;
        margin-bottom: 10px;
        padding: 15px;
        border-left: 5px solid #86759D;
        transition: all 0.3s ease;
    }

    .intro-list,
    .objectives-list li:hover,
    .conclusions-list li:hover {
        transform: translateX(5px);
        box-shadow: 0 2px 5px rgba(0, 0, 0, 0.1);
    }

    .method-grid {
        display: grid;
        grid-template-columns: repeat(2, 1fr);
        gap: 20px;
    }

    .method-item {
        background-color: #f2f2f2;
        padding: 15px;
        border-radius: 8px;
        text-align: center;
        transition: all 0.3s ease;
    }

    .method-item p {
        text-align: left;
    }

    .method-icon {
        font-size: 24px;
        margin-bottom: 10px;
    }

    .method-title {
        font-weight: bold;
        margin-bottom: 5px;
    }

    .footer {
        display: flex;
        justify-content: space-between;
        padding: 10px;
    }

    .footer-section {
        flex: 1;
        background-color: transparent;
        padding: 1px;
    }

    .footer-title {
        font-size: 1.3em;
        font-weight: bold;
        color: #2F4890;
        margin-bottom: 10px;
    }

    .footer-content {
        font-size: 0.8em;
        color: #555;
    }

    @media (max-width: 768px) {
        .section-block {
            flex-direction: column;
            gap: 0px;
        }

        .section:first-child,
        .section:last-child {
            flex: 1 1 auto;
            max-width: 50%;
        }

        .objectives-list {
            height: auto;
        }

        .graph-notes {
            display: flex;
            flex-direction: column;
            justify-content: space-between;
            list-style-type: none;
            padding-left: 0;
            margin-top: 15px;
        }

        .graph-notes li {
            background-color: #F2F2F2;
            margin-bottom: 10px;
            padding: 15px;
            border-left: 5px solid #86759D;
            transition: all 0.3s ease;
        }

        .graph-notes li:hover {
            transform: translateX(5px);
            box-shadow: 0 2px 5px rgba(0, 0, 0, 0.1);
        }
    }
</style>

<body>
    <div class="header">
        <img src="https://www.hsph.harvard.edu/takemi/wp-content/uploads/sites/114/2024/06/cropped-Group.jpg"
            alt="Harvard T.H. Chan School of Public Health | Takemi Program in International Health">
    </div>
    <div class="main-content">
        <div class="intro-objectives">
            <div class="section">
                <p class="section-title">Introduction</p>
                <ul class="intro-list">
                    <li>Globally, 39 million people were living with HIV at the end of 2022 with three quarters of these
                        individuals living across the sub-Saharan African (SSA) region.</li>
                    <li>Since 2018, millions of people living with HIV (PLWH) started transitioning from the previous
                        non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART)
                        regimens to dolutegravir (DTG)- based ART.</li>
                    <li>DTG is an optimal drug of choice for first-line ART due to its higher potency, genetic barrier
                        to resistance and shorter time to suppression. With the aim of ending the AIDS epidemic by 2030,
                        one of the UNAIDS 95-95-95 agenda aims at ensuring virological suppression of PLWH and accessing
                        treatment. Therefore, it is important to assess progress especially in the context of newer
                        treatment strategies.</li>
                </ul>
            </div>
            <div class="section">
                <p class="section-title">Objectives</p>
                <ul class="objectives-list">
                    <li>Assess virological suppression rates of PLWH transitioning to DTG-based ART after 24 months of
                        transition in Abuja, Nigeria.</li>
                    <li>Characterize the determinants of virological suppression using regression analysis.</li>
                </ul>
            </div>
        </div>
    </div>
    <div class="section">
        <p class="section-title">Methods</p>
        <div class="method-grid">
            <div class="method-item">
                <div class="method-icon">&#x1f4dd;</div>
                <div class="method-title">Design</div>
                <p>Retrospective population level data analysis from 2018- 2019 from 33,982 participants</p>
            </div>
            <div class="method-item">
                <div class="method-icon">&#x1f4cd;</div>
                <div class="method-title">Setting</div>
                <p> Nigeria (Electronic data abstraction in Abuja, Nigeria)</p>
            </div>
            <div class="method-item">
                <div class="method-icon">&#x1f465;</div>
                <div class="method-title">Participants</div>
                <p>Adult PLWH (≥15 years) transitioning to DTG-based regimen</p>
            </div>
            <div class="method-item">
                <div class="method-icon">&#x1f50d;</div>
                <div class="method-title">Outcome measure</div>
                <p>Virological suppression after 12 and 24 months of participants followed for up to two years</p>.
            </div>
            <div class="method-item">
                <div class="method-icon">&#x1f4ca;</div>
                <div class="method-title">Analysis</div>
                <p> Evaluation of virological suppression rates (HIV viral load ≤50 copies/mL) at 12M and 24M following
                    DTG transition and evaluation of determinants of suppression outcome using Poisson regression
                    analysis</p>
            </div>
        </div>
    </div>
    <div class="section">
        <p class="section-title">Key Findings</p>
        <div class="button-container">
            <button class="expand-btn active" onclick="toggleContent('participant-characteristics', this)">Participant
                Characteristics</button>
            <button class="expand-btn" onclick="toggleContent('virological-suppression-rates', this)">Virological
                Supression Rates</button>
        </div>
        <div id="participant-characteristics">
            <div class="interactive-element">
                <p class="section-subtitle">Participant Characteristics</p>
                <iframe src='https://flo.uri.sh/story/2444479/embed' title='Interactive or visual content'
                    class='flourish-embed-iframe' frameborder='0' scrolling='no' style='width:100%;height:600px;'
                    sandbox='allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation'></iframe>
                <div style='width:100%!;margin-top:4px!important;text-align:right!important;'><a class='flourish-credit'
                        href='https://public.flourish.studio/story/2444479/?utm_source=embed&utm_campaign=story/2444479'
                        target='_top' style='text-decoration:none!important'><img alt='Made with Flourish'
                            src='https://public.flourish.studio/resources/made_with_flourish.svg'
                            style='width:105px!important;height:16px!important;border:none!important;margin:0!important;'>
                    </a></div>
            </div>
            <ul class="graph-notes">
                <li>27,608/33,982 (81.2%) had viral load data available at 12M and 25,990/33,982 (76.4%) at 24M</li>
                <li>Most participants were females 21,930/33,982 (65%) with median age of 38 years (IQR: 32, 45)</li>
                <li>Virological suppression rates at 12M was 22,006/27,608 (79.7%) and 24M was 21,320/25,990 (82%)</li>
                <li>Higher rates of suppression was observed in switchers relative to starters at 12M and 24M.</li>
            </ul>
        </div>
        <div id="virological-suppression-rates" class="hidden">
            <div class="interactive-element">
                <p class="section-subtitle">Virological Suppression Rates</p>
                <iframe src='https://flo.uri.sh/story/2439749/embed' title='Interactive or visual content'
                    class='flourish-embed-iframe' frameborder='0' scrolling='no' style='width:100%;height:600px;'
                    sandbox='allow-same-origin allow-forms allow-scripts allow-downloads allow-popups allow-popups-to-escape-sandbox allow-top-navigation-by-user-activation'></iframe>
                <div style='width:100%!;margin-top:4px!important;text-align:right!important;'><a class='flourish-credit'
                        href='https://public.flourish.studio/story/2439749/?utm_source=embed&utm_campaign=story/2439749'
                        target='_top' style='text-decoration:none!important'><img alt='Made with Flourish'
                            src='https://public.flourish.studio/resources/made_with_flourish.svg'
                            style='width:105px!important;height:16px!important;border:none!important;margin:0!important;'>
                    </a></div>
            </div>
            <ul class="graph-notes">
                <li>In adjusted Poisson regression analysis, switcher status and female gender were the strongest
                    predictors of virological suppression at 12M and 24M.</li>
                <li>Access to antiretroviral care at tertiary health facilities and older age were also predictors of
                    virological suppression at 12M and 24M.</li>
            </ul>
        </div>
    </div>
    <div class="section">
        <p class="section-title">Conclusions and Recommendations</p>
        <ul class="conclusions-list">
            <li>In the DTG era, evidence suggests robust virological response following transition with overall,
                suppression rates ≈ 80%.</li>
            <li>Low level viraemia was common and to a lesser extent, virological non-suppression; overall higher
                frequency in DTG starters relative to switchers. </li>
            <li>Sub-optimal retention rates in care with likely population level impact of continuous transmission.
            </li>
            <li>Our full results support the continued scale-up of DTG as drug of choice in Nigeria with virological
                monitoring, drug resistance and adherence support to improve retention in care.</li>
        </ul>
    </div>
    <div class="section-block footer">
        <div class="footer-section">
            <p class="footer-title">Acknowledgements</p>
            <p class="footer-content">Professor Veronika Wirtz and Dr. Jesse Bump were project advisors. Professor Aya
                Goto provided helpful suggestions. Oyeronke Oyebanji (CEPI), Sourabh Sobti (CEPI), and Dr. Stephen B.
                Kennedy (PREVAIL, Monrovia, Liberia) all facilitated the conduct of this research.</p>
            <p class="footer-content">No funding support was provided. No human subjects were involved in this research.
            </p>
        </div>
        <div class="footer-section">
            <p class="footer-title">References</p>
            <ol class="footer-content">
                <li><a href="https://www.medbox.org/index.php/document/fact-sheet-global-aids-update-2019">UNAIDS, “FACT
                        SHEET – GLOBAL AIDS UPDATE 2019,” 2019.</a></li>
                <li><a href="https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15">World Health Organization,
                        “Update of recommendations on first- and second-line antiretroviral regimens,” 2019.</a></li>
            </ol>
        </div>
    </div>
    <script>
        function toggleContent(id, button) {
            var contents = document.querySelectorAll('#participant-characteristics, #virological-suppression-rates');
            contents.forEach(function (content) {
                content.classList.add('hidden');
            });
            var buttons = document.querySelectorAll('.expand-btn');
            buttons.forEach(function (btn) {
                btn.classList.remove('active');
            });
            var content = document.getElementById(id);
            content.classList.remove('hidden');
            button.classList.add('active');
        }
        window.onload = function () {
            var firstButton = document.querySelector('.expand-btn');
            var firstContentId = 'participant-characteristics';
            toggleContent(firstContentId, firstButton);
        };
    </script>
</body>
